This ETF Invests in Firms with Significant Insider Purchases - DVDN
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Should l Buy TRIN?
Source: NASDAQ.COM
Insider Buying Activity: The Kingsbarn Dividend Opportunity ETF (DVDN) has 29.9% of its weighted holdings showing insider buying in the past six months.
Trinity Capital Inc (TRIN): TRIN, making up 6.80% of DVDN, has had 3 directors and officers purchase shares recently, with the ETF holding $225,758 worth of TRIN.
Angel Oak Mortgage REIT Inc (AOMR): AOMR, the #16 largest holding in DVDN, has seen 2 directors and officers file Form 4s for share purchases, with the ETF holding $136,902 worth of AOMR.
Disclaimer: The views expressed in the article are those of the author and do not necessarily reflect the opinions of Nasdaq, Inc.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRIN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRIN
Wall Street analysts forecast TRIN stock price to rise
6 Analyst Rating
5 Buy
0 Hold
1 Sell
Moderate Buy
Current: 14.470
Low
13.50
Averages
16.50
High
17.50
Current: 14.470
Low
13.50
Averages
16.50
High
17.50
About TRIN
Trinity Capital Inc. is an internally managed, closed-end, non-diversified management investment company that operates as a business development company. It is a specialty lending company that provides debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its investment objective is to generate current income and capital appreciation through its investments across five vertical markets. It seeks to achieve its investment objective by making investments consisting primarily of term loans and equipment financings and working capital loans, equity and equity-related investments. Its equipment financings involve loans for general or specific use, including acquiring equipment that is secured by the equipment or other assets of the portfolio company. It targets investments in growth-stage companies that are typically private companies, including institutional investor-based companies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trinity Capital Declares Consistent Dividends for Q2 2026
- Consistent Dividends: Trinity Capital has declared a monthly dividend of $0.17 per share for April, May, and June 2026, maintaining over six years of stable dividends, which reflects the company's strong cash flow and profitability.
- Dividend Payment Schedule: The payment dates for dividends in April, May, and June 2026 are set for April 30, May 29, and June 30, respectively, ensuring timely returns for shareholders and enhancing investor confidence.
- Tax Compliance Objective: The company aims to distribute dividends approximating 90% to 100% of its taxable quarterly income to qualify as a regulated investment company under the Internal Revenue Code of 1986, ensuring tax compliance.
- Portfolio Performance: Since its inception in 2008, Trinity Capital has deployed over $5.5 billion across 463 investments, showcasing its robust presence in the private credit market and ongoing growth potential.
See More
Trinity Capital Commits $35 Million to Monteris Medical for Growth
- Investment Amount: Trinity Capital announced a commitment of $35 million to Monteris Medical, reflecting confidence and support for the growth in the MedTech sector focused on minimally invasive surgical technologies.
- Technology Background: The NeuroBlate System developed by Monteris Medical is a robotically controlled laser interstitial thermal therapy platform that utilizes MRI-guided technology to remove abnormal brain tissue, aiming to provide a less invasive alternative to traditional open neurosurgery.
- Clinical Impact: The system is designed to help patients experience lower complication rates and shorter hospital stays, enhancing overall treatment experiences, which aligns with the current healthcare industry's demand for efficient and safe treatment options.
- Commercialization Support: The funding will support the commercialization of the NeuroBlate System and the expansion of clinical research programs, which is expected to enhance Monteris Medical's competitiveness and business growth in the market.
See More
Trinity Capital Commits $35 Million to Monteris Medical for Growth Capital
- Investment Scale: Trinity Capital has committed $35 million to Monteris Medical to support the commercialization of its NeuroBlate System and the expansion of clinical research, thereby driving innovation in medical technology.
- Technological Advantage: The NeuroBlate System utilizes robotically controlled laser interstitial thermal therapy to precisely remove abnormal brain tissue, offering patients lower complication rates and shorter hospital stays compared to traditional open neurosurgery, significantly enhancing patient treatment experiences.
- Market Outlook: Monteris Medical's technology is expanding treatment options in neurosurgery, and Trinity Capital's investment not only strengthens its market competitiveness but also reflects strong confidence in its strategy and technology, indicating a promising future in the life sciences sector.
- Partnership Confidence: The CEO of Monteris Medical stated that this financing will accelerate growth and drive innovation, indicating that the collaboration with Trinity Capital will provide robust support for its clinical impact across neuroscience centers.
See More
Trinity Capital Commits $35 Million to Monteris Medical for NeuroBlate System
- Investment Amount: Trinity Capital has announced a commitment of $35 million to Monteris Medical to support the commercialization of its NeuroBlate System and the expansion of clinical research, thereby driving innovation in medical technology.
- Technological Advantage: The NeuroBlate System utilizes robotically controlled laser technology to treat brain tumors and drug-resistant epilepsy with minimal invasiveness, significantly reducing patient complication rates and hospital stays while improving quality of life.
- Market Outlook: Monteris Medical's innovative technology is expanding treatment options in neurosurgery, and Trinity Capital's investment not only enhances its market competitiveness but also provides safer and more effective treatment options for patients, aligning with industry trends.
- Strategic Partnership: Trinity Capital's investment reflects strong confidence in Monteris Medical's strategy, expected to accelerate its clinical impact across neuroscience centers and further drive product innovation and commercial expansion.
See More
TRINITY CAPITAL PLEDGES $35 MILLION IN GROWTH CAPITAL TO MONTERIS MEDICAL
- Investment Announcement: Trinity Capital has committed $35 million in growth capital to Monteris Medical.
- Purpose of Funding: The investment aims to support Monteris Medical's expansion and development in the medical sector.
See More
Trinity Capital Commits $20 Million to Emboline for Growth Capital
- Funding Commitment: Trinity Capital has announced a $20 million investment in medical technology company Emboline to support the commercial launch of its Emboliner embolic protection catheter, aimed at reducing the risk of strokes and other complications during minimally invasive heart procedures.
- Clinical Trial Progress: Emboline has recently completed patient enrollment in the PROTECT H2H investigational device exemption clinical trial, which is crucial for generating the data needed for regulatory approval, indicating the company's proactive steps towards product commercialization.
- Manufacturing Expansion: This financing will enable Emboline to scale its manufacturing capabilities, expand its team, and support clinical and regulatory milestones, thereby laying a solid foundation for the successful launch of its product.
- Market Outlook: Trinity Capital's investment not only reflects confidence in Emboline's technology but also indicates a strategic positioning in the medical device sector, which is expected to enhance the company's competitiveness in the rapidly growing healthcare market.
See More
Trinity Capital Declares Consistent Dividends for Q2 2026
- Consistent Dividends: Trinity Capital has declared a monthly dividend of $0.17 per share for April, May, and June 2026, maintaining over six years of stable dividends, which reflects the company's strong cash flow and profitability.
- Dividend Payment Schedule: The payment dates for dividends in April, May, and June 2026 are set for April 30, May 29, and June 30, respectively, ensuring timely returns for shareholders and enhancing investor confidence.
- Tax Compliance Objective: The company aims to distribute dividends approximating 90% to 100% of its taxable quarterly income to qualify as a regulated investment company under the Internal Revenue Code of 1986, ensuring tax compliance.
- Portfolio Performance: Since its inception in 2008, Trinity Capital has deployed over $5.5 billion across 463 investments, showcasing its robust presence in the private credit market and ongoing growth potential.
See More
Trinity Capital Commits $35 Million to Monteris Medical for Growth
- Investment Amount: Trinity Capital announced a commitment of $35 million to Monteris Medical, reflecting confidence and support for the growth in the MedTech sector focused on minimally invasive surgical technologies.
- Technology Background: The NeuroBlate System developed by Monteris Medical is a robotically controlled laser interstitial thermal therapy platform that utilizes MRI-guided technology to remove abnormal brain tissue, aiming to provide a less invasive alternative to traditional open neurosurgery.
- Clinical Impact: The system is designed to help patients experience lower complication rates and shorter hospital stays, enhancing overall treatment experiences, which aligns with the current healthcare industry's demand for efficient and safe treatment options.
- Commercialization Support: The funding will support the commercialization of the NeuroBlate System and the expansion of clinical research programs, which is expected to enhance Monteris Medical's competitiveness and business growth in the market.
See More
Trinity Capital Commits $35 Million to Monteris Medical for Growth Capital
- Investment Scale: Trinity Capital has committed $35 million to Monteris Medical to support the commercialization of its NeuroBlate System and the expansion of clinical research, thereby driving innovation in medical technology.
- Technological Advantage: The NeuroBlate System utilizes robotically controlled laser interstitial thermal therapy to precisely remove abnormal brain tissue, offering patients lower complication rates and shorter hospital stays compared to traditional open neurosurgery, significantly enhancing patient treatment experiences.
- Market Outlook: Monteris Medical's technology is expanding treatment options in neurosurgery, and Trinity Capital's investment not only strengthens its market competitiveness but also reflects strong confidence in its strategy and technology, indicating a promising future in the life sciences sector.
- Partnership Confidence: The CEO of Monteris Medical stated that this financing will accelerate growth and drive innovation, indicating that the collaboration with Trinity Capital will provide robust support for its clinical impact across neuroscience centers.
See More
Trinity Capital Commits $35 Million to Monteris Medical for NeuroBlate System
- Investment Amount: Trinity Capital has announced a commitment of $35 million to Monteris Medical to support the commercialization of its NeuroBlate System and the expansion of clinical research, thereby driving innovation in medical technology.
- Technological Advantage: The NeuroBlate System utilizes robotically controlled laser technology to treat brain tumors and drug-resistant epilepsy with minimal invasiveness, significantly reducing patient complication rates and hospital stays while improving quality of life.
- Market Outlook: Monteris Medical's innovative technology is expanding treatment options in neurosurgery, and Trinity Capital's investment not only enhances its market competitiveness but also provides safer and more effective treatment options for patients, aligning with industry trends.
- Strategic Partnership: Trinity Capital's investment reflects strong confidence in Monteris Medical's strategy, expected to accelerate its clinical impact across neuroscience centers and further drive product innovation and commercial expansion.
See More
TRINITY CAPITAL PLEDGES $35 MILLION IN GROWTH CAPITAL TO MONTERIS MEDICAL
- Investment Announcement: Trinity Capital has committed $35 million in growth capital to Monteris Medical.
- Purpose of Funding: The investment aims to support Monteris Medical's expansion and development in the medical sector.
See More
Trinity Capital Commits $20 Million to Emboline for Growth Capital
- Funding Commitment: Trinity Capital has announced a $20 million investment in medical technology company Emboline to support the commercial launch of its Emboliner embolic protection catheter, aimed at reducing the risk of strokes and other complications during minimally invasive heart procedures.
- Clinical Trial Progress: Emboline has recently completed patient enrollment in the PROTECT H2H investigational device exemption clinical trial, which is crucial for generating the data needed for regulatory approval, indicating the company's proactive steps towards product commercialization.
- Manufacturing Expansion: This financing will enable Emboline to scale its manufacturing capabilities, expand its team, and support clinical and regulatory milestones, thereby laying a solid foundation for the successful launch of its product.
- Market Outlook: Trinity Capital's investment not only reflects confidence in Emboline's technology but also indicates a strategic positioning in the medical device sector, which is expected to enhance the company's competitiveness in the rapidly growing healthcare market.
See More
